AbbVie (ABBV)
(Delayed Data from NYSE)
$195.45 USD
-1.37 (-0.70%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $194.88 -0.57 (-0.29%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$195.45 USD
-1.37 (-0.70%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $194.88 -0.57 (-0.29%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Zacks News
Amgen (AMGN) Q4 Earnings & Sales Top, 2021 Outlook Dull
by Zacks Equity Research
Amgen (AMGN) beats Q4 estimates for both earnings and sales. Shares decline in after-hours trading.
Will Humira, Cancer Drugs Drive AbbVie (ABBV) Q4 Earnings?
by Zacks Equity Research
AbbVie's (ABBV) Q4 top line is expected to have witnessed a recovery in demand amid improving global economies. However, resurgence of COVID-19 cases is likely to have hurt sales of physician-administered drugs.
Buy Pharma Giant AbbVie Stock Before Q4 Earnings for Dividend and Value?
by Benjamin Rains
Let's check out AbbVie to see if investors might want to buy the stock ahead of its fourth quarter fiscal 2020 financial release that's due out before the opening bell on Wednesday, Feb. 3...
Will Recovery in AbbVie's (ABBV) Earnings Continue in Q4?
by Zacks Equity Research
Recovery in AbbVie's (ABBV) revenues is likely to have continued in the fourth quarter. Investors focus is likely to be on 2021 guidance when the company reports results in the wake of rising cases.
Pharma Stock Roundup: JNJ, NVS Q4 Earnings, MRK & LLY's Coronavirus Updates
by Kinjel Shah
J&J (JNJ) and Novartis (NVS) announce Q4 results. Merck (MRK), AbbVie (ABBV) & Pfizer (PFE) get EU approvals.
AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $104.21, moving +1.38% from the previous trading session.
AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $108.80 in the latest trading session, marking a -1.54% move from the prior day.
J&J (JNJ) Q4 Earnings & Sales Beat, 2021 Guidance Upbeat
by Zacks Equity Research
J&J (JNJ) beats fourth-quarter 2020 estimates for both earnings and sales. It issues its adjusted earnings and sales outlook for 2021. Stock up.
J&J (JNJ) to Get the Ball Rolling for Pharma Q4 Earnings
by Zacks Equity Research
J&J's (JNJ) Pharma segment is expected to have performed above market while continued procedure stabilization is expected to have benefited the Medical Devices segment in the fourth quarter.
AbbVie (ABBV) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $112.62, marking a +0.39% move from the previous day.
Bausch Health (BHC) Dry Eye Treatment Study Enrollment Complete
by Zacks Equity Research
Bausch Health (BHC) and Novaliq GmbH complete enrollment in first of the two phase III studies evaluating NOV03 to treat the signs and symptoms of Dry eye disease associated with MGD.
Top Stock Reports for Novartis, QUALCOMM & Accenture
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Novartis (NVS), QUALCOMM (QCOM), and Accenture (ACN).
Editas (EDIT) Up More Than 100% in Past 3 Months: Here's Why
by Zacks Equity Research
Editas' (EDIT) lead candidate EDIT-101, that employs CRISPR gene editing to treat LCA10, holds potential. The company is also developing EDIT-301 for treating SCD.
AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $111.63 in the latest trading session, marking a -0.73% move from the prior day.
AbbVie (ABBV) Inks Deal to Acquire Medical Device Company
by Zacks Equity Research
AbbVie (ABBV) signs an agreement to acquire privately held Cypris Medical, including the latter's Xact device which is used for performing face and neck lifts.
AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $109.78 in the latest trading session, marking a +0.7% move from the prior day.
Novartis (NVS) In-Licenses Anti-PD-1 Antibody from BeiGene
by Zacks Equity Research
Novartis (NVS) in-licenses BeiGene's anti-PD-1 monoclonal antibody, tislelizumab, in major markets outside of China.
AbbVie (ABBV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $109.02 in the latest trading session, marking a +1.63% move from the prior day.
Pharma Stock Roundup: ABBV's Positive Skyrizi Data, AZN, PFE, RHHBY's FDA Updates
by Kinjel Shah
AbbVie's (ABBV) Skyrizi succeeds in psoriatic arthritis and Crohn's disease studies. AstraZeneca (AZN), Pfizer (PFE) and Roche (RHHBY) give FDA updates.
AbbVie's (ABBV) Skyrizi Succeeds in Crohn's Disease Studies
by Zacks Equity Research
AbbVie's (ABBV) Skyrizi achieves improvements in clinical remission and endoscopic response in phase III studies in moderate to severe Crohn's disease patients.
3 Biotech Technological Developments to Watch Out For in 2021
by Kinjel Shah
Here we discuss three booming technological developments in the biotech sector, which can capture investor attention in 2021
Why AbbVie (ABBV) Could Beat Earnings Estimates Again
by Zacks Equity Research
AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
AbbVie's (ABBV) Skyrizi Succeeds in Psoriatic Arthritis Studies
by Zacks Equity Research
AbbVie's (ABBV) Skyrizi achieves improvements in disease activity across joint and skin symptoms in phase III studies in active psoriatic arthritis.
AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $106.50 in the latest trading session, marking a +1.03% move from the prior day.
Biohaven (BHVN) Initiates Pivotal Study on OCD Candidate
by Zacks Equity Research
Biohaven (BHVN) initiates enrollment in a phase III study to evaluate troriluzole as adjunctive treatment for patients with obsessive-compulsive disorder.